Vol. 21/No. 2

Josep Tabernero, MD, PHD, MSc, is best known for applying translational research against gastrointestinal tumors, with particular focus on colorectal cancer.

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Although small molecule inhibitors of the Hedgehog signaling pathway have transformed the treatment paradigm for advanced basal cell carcinoma, the most common form of skin cancer, efforts to expand their use to other tumor types have proved elusive.

Anecdotes of gender inequality and sexual harassment abound among gynecologic oncologists, but until recently, there had been no study to measure the problem in this profession. Findings reported in June 2019 suggesting that high numbers of men and women in this field were subject to sexual harassment were no surprise to investigators. Instead, they have strengthened national gender discrimination and sexual harassment reform efforts in oncologic gynecology.

Investigators hope to answer a potentially paradigm-changing question in the phase II ANCHOR-CRC study (NCT03693170) of BRAF V600E–mutant colorectal cancer (CRC): Can the benefit observed with a targeted triplet in latestage disease extend to the first line?

The 37th Annual Miami Breast Cancer Conference provides practical guidance on cutting-edge developments in the treatment of breast cancer.

Between 2013 and 2017, just 40% of patients with metastatic colon cancer received guideline-recommended biomarker testing that could have improved treatment decisions, according to findings from a retrospective study. Results also showed that adherence to evidence-based recommendations for genotyping was poor in academic and community settings alike.

PARP inhibitors are poised to acquire a stronger foothold in the frontline setting for advanced ovarian cancer, for which chemotherapy remains the backbone of treatment, according to a panel of gynecologic oncology experts who discussed the issue during an OncLive Peer Exchange® held during the European Society for Medical Oncology Congress 2019.

A prognostic, deep-learning model developed by investigators at Cleveland Clinic’s Taussig Cancer Institute in Ohio and collaborators brings radiation oncology into the realm of personalized medicine.

Even the most basic investigation into fundamental mechanisms of the development and progression of cancer in an in vitro system may generate data that, ultimately, prove vital to developing new approaches to prevent, diagnose, and treat malignant disease.